Breaking News Instant updates and real-time market news.

SNY

Sanofi

$40.68

0.03 (0.07%)

11:15
03/13/18
03/13
11:15
03/13/18
11:15

Sanofi has a conference call hosted by JPMorgan

JPMorgan Analyst Vosser will host a conference call with CEO Olivier Brandicourt on March 13 at 11:30 am.

  • 13

    Mar

  • 25

    Mar

  • 02

    May

SNY Sanofi
$40.68

0.03 (0.07%)

03/12/18
PIPR
03/12/18
NO CHANGE
Target $182
PIPR
Overweight
Piper says Sanofi decision not to op-in on lumasiran positve for Alnylam
Piper Jaffray analyst Edward Tenthoff said he views Sanofi's (SNY) decision not to opt-in for global rights on lumasiran for the treatment of Primary Hyperoxaluria Type 1, or PH1, as a positive for Alnylam (ALNY), as he believes lumasiran could represent a fourth RNAi therapy with potential approval by 2020. Tenthoff, who said he is confident in FDA approval of patisiran by the August 11 PDUFA date and expects givosiran approval in 2019, keeps an Overweight rating and $182 target on Alnylam shares.
03/12/18
RILY
03/12/18
NO CHANGE
Target $200
RILY
Buy
Alnylam bear argument undercut by Regeneron data, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar believes this weekend's Odyssey Outcomes data from Regeneron (REGN) and Sanofi (SNY) undercuts the bear argument on Alnylam Pharmaceuticals (ALNY) that PCSK9 drugs do not demonstrate clinically meaningful mortality benefit. Further, the analyst believes Sanofi and Regeneron's lower Praluent pricing in high-risk patients will likely expand uptake of PCSK9 drugs in the cholesterol market. Kumar keeps a Buy rating on Alnylam with a $200 price target.
02/26/18
LEER
02/26/18
NO CHANGE
LEER
Leerink remains positive on Regeneron/Sanofi Dupixent
Leerink analyst Geoffrey Porges says sentiment about the revenue potential of Regeneron (REGN)/Sanofi's (SNY) Dupixent has been declining over the past year, despite an impressive launch, and a steady flow of data for new indications and populations. The analyst remains positive about the product, forecasting 2020 revenue of $4B and growing to $6.5B by 2022 and $7.8B by 2025 from multiple indications.
02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$42.33

0.25 (0.59%)

07:29
08/21/18
08/21
07:29
08/21/18
07:29
Recommendations
Pfizer analyst commentary  »

Pfizer price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 25

    Aug

  • 27

    Aug

  • 05

    Sep

  • 10

    Sep

  • 12

    Sep

  • 26

    Sep

  • 17

    Oct

FB

Facebook

$172.50

-1.28 (-0.74%)

, AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

07:29
08/21/18
08/21
07:29
08/21/18
07:29
Periodicals
Engineer discovers UI for Facebook's rumored Aloha AI assistant, TNW reports »

Facebook (FB) is…

FB

Facebook

$172.50

-1.28 (-0.74%)

AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

GOOG

Alphabet

$1,207.54

7.75 (0.65%)

GOOGL

Alphabet Class A

$1,221.18

5.68 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

AZN

AstraZeneca

$38.85

0.72 (1.89%)

07:28
08/21/18
08/21
07:28
08/21/18
07:28
Hot Stocks
AstraZeneca announces Japanese approval of Tagrisso for first-line NSCLC »

AstraZeneca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Aug

COST

Costco

$227.35

1.68 (0.74%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
Costco analyst commentary  »

Costco price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Oct

LB

L Brands

$33.07

0.53 (1.63%)

07:26
08/21/18
08/21
07:26
08/21/18
07:26
Recommendations
L Brands analyst commentary  »

L Brands price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

MGM

MGM Resorts

$28.59

0.035 (0.12%)

, CZR

Caesars

$10.05

0.05 (0.50%)

07:25
08/21/18
08/21
07:25
08/21/18
07:25
Recommendations
MGM Resorts, Caesars analyst commentary  »

Room survey suggests…

MGM

MGM Resorts

$28.59

0.035 (0.12%)

CZR

Caesars

$10.05

0.05 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$225.37

2.76 (1.24%)

07:24
08/21/18
08/21
07:24
08/21/18
07:24
Initiation
Lennox initiated  »

Lennox initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

HCSG

Healthcare Services

$41.33

0.11 (0.27%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Conference/Events
Healthcare Services management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 29

    Aug

GTT

GTT Communications

$38.30

-0.7 (-1.79%)

07:23
08/21/18
08/21
07:23
08/21/18
07:23
Recommendations
GTT Communications analyst commentary  »

GTT Communications should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOE

Ferro

$21.23

-0.06 (-0.28%)

07:22
08/21/18
08/21
07:22
08/21/18
07:22
Conference/Events
Ferro management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 11

    Sep

TSS

TSYS

$94.88

-0.01 (-0.01%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Recommendations
TSYS analyst commentary  »

TSYS price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 17

    Sep

  • 06

    Nov

FITB

Fifth Third

$29.83

0.145 (0.49%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
Fifth Third management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 23

    Oct

YRCW

YRC Worldwide

$9.11

0.11 (1.22%)

07:21
08/21/18
08/21
07:21
08/21/18
07:21
Conference/Events
YRC Worldwide management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 06

    Nov

MDT

Medtronic

$90.06

-0.54 (-0.60%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Hot Stocks
Breaking Hot Stocks news story on Medtronic »

Medtronic up 4.4% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 05

    Sep

  • 12

    Sep

ECOM

ChannelAdvisor

$12.95

-0.15 (-1.15%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Conference/Events
ChannelAdvisor management to meet with KeyBanc »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 23

    Aug

  • 28

    Aug

  • 06

    Sep

  • 07

    Sep

JCI

Johnson Controls

$38.73

0.48 (1.25%)

07:20
08/21/18
08/21
07:20
08/21/18
07:20
Upgrade
Johnson Controls rating change  »

Johnson Controls upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.62

-0.13 (-0.11%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Periodicals
JPMorgan to launch new investing app for free, CNBC reports »

JPMorgan has plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 26

    Feb

DLB

Dolby

$68.32

-0.75 (-1.09%)

07:19
08/21/18
08/21
07:19
08/21/18
07:19
Conference/Events
Dolby management to meet with William Blair »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 06

    Sep

EPAM

Epam Systems

$136.36

1.355 (1.00%)

07:18
08/21/18
08/21
07:18
08/21/18
07:18
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRZO

Carrizo Oil & Gas

$22.79

0.05 (0.22%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Conference/Events
Carrizo Oil & Gas management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

BBY

Best Buy

$79.39

0.91 (1.16%)

, AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
Best Buy, Amazon.com analyst commentary  »

Best Buy valuation…

BBY

Best Buy

$79.39

0.91 (1.16%)

AMZN

Amazon.com

$1,875.45

-6.49 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

ACRS

Aclaris Therapeutics

$16.01

0.34 (2.17%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Hot Stocks
Aclaris Therapeutics announces ATI-450 findings in publication »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$53.81

0.51 (0.96%)

07:17
08/21/18
08/21
07:17
08/21/18
07:17
Recommendations
U.S. Bancorp analyst commentary  »

U.S. Bancorp capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRON

Cronos Group

$7.33

0.78 (11.91%)

07:16
08/21/18
08/21
07:16
08/21/18
07:16
Hot Stocks
Cronos Group announces initial supply agreement for retail distribution »

Cronos Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOME

At Home Group

$34.01

0.06 (0.18%)

07:15
08/21/18
08/21
07:15
08/21/18
07:15
Recommendations
At Home Group analyst commentary  »

At Home Group's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.